External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setback</li><li>Perceptive Advisors increased stake in anticipation of reproxalap approval for dry eye disease</li><li>Potential option agreement with AbbVie could greatly benefit ALDX financially, making its share price undervalued</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setbackPerceptive Advisors increased stake in anticipation of reproxalap approval for dry eye diseasePotential option agreement with AbbVie could greatly benefit ALDX financially, making its share price undervaluedThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Aldeyra Therapeutics Inc (ALDX) - Wednesday, Apr 10, 2024

United States

Merrimack Pharmaceuticals, Inc. operates as a biotechnology company. The Company focuses on the discovery and development of drugs for the treatment of immunological and autoimmune diseases. Merrimack Pharmaceuticals serves patients in the United States.

Agenus, Inc. develops vaccines.  The Company researches vaccines for brain cancer, kidney cancer, herpes, lung cancer, melanoma, malaria, shingles, and Alzheimer's disease.

Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company. The Company develops novel gene therapies for life-threatening rare diseases.

Spectrum Pharmaceuticals Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company's strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.

Bluebird Bio, Inc. provides biotechnological products and services. The Company offers gene therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders, and beta-thalassemia. Bluebird Bio conducts its business in the United States.

Actinium Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops pipeline of antibody radiation conjugates for targeted conditioning and combination therapies. Actinium Pharmaceuticals serves clients in the United States.

Mersana Therapeutics, Inc. produces novel drug conjugates. The Company specializes in oncology agents for the treatment of tumors and cancer. Mersana Therapeutics serves the healthcare industry in the United States.

AVITA Medical, Inc. operates as a medicine company. The Company focuses on the development and commercialization of therapies to address unmet medical needs in patients with burns, chronic wounds, and aesthetics indications. AVITA Medical serves customers worldwide.

Gossamer Bio, Inc. operates as a biopharmaceutical company. The Company focuses on discovering, acquiring, and developing therapeutics in the disease areas of immunology, inflammation, and oncology. Gossamer Bio serves customers in the United States.

Seres Therapeutics, Inc. operates as a microbiome therapeutics platform company. The Company focuses on developing biological drugs, which are designed to restore health by repairing the function of a dysbiotic microbiome. Seres Therapeutics also conducts research on metabolic diseases.

Genexine Co., Ltd. is bio technology company. The Company specialize in the development of therapeutic vaccines and next generation antibody fusion protein medications.

Dimerix Limited operates as a biotechnology company. The Company focuses on developing and marketing drug therapies, as well as provides clinical trials for treating patients with chronic kidney diseases. Dimerix serves patients in Australia.

Pharma Foods International Co.,Ltd. produces and sells bioengineered foods for commercial use.  The Company researches and develops physiologically functional foods.

Pharmicell Co.,Ltd. is a Biotechnology company.  The Company's business area inlcudes stem cell therapeutics, Stem cell banking, Bio-based business and Cosmetics.

Avita Medical Limited is a biotechnology company which develops and distributes tissue-engineered cellular products for skin replacement. The Company's products include CellSpray and ReCell, which are used for the treatment of burns and other skin injuries, previous scarring, chronic wounds and cosmetic procedures.

Xinjiang Tianshan Animal Husbandry Bio-engineering Co Ltd develops cattle breed and genetic improvements. The Company's main products include high quality cattle semen, embryos as well as other genetic material and related services.

Xinjiang Tianshan Animal Husba (300313 CH)

Amicogen, Inc. develops, produces and markets specialty enzymes and functional food ingredients. The Company offers special biocatalysts,  enzyme-based new functional materials, health foods, and consumer products.

Immutep Limited operates as a biotechnology company. The Company focuses on developing novel immunotherapy treatments for cancer and autoimmune disease. Immutep offers its services worldwide.

Molecular Partners AG develops and markets biopharmaceutical products. The Company develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments. Molecular Partners serves healthcare professionals and patients internationally.

Nanobiotix operates as a late clinical-stage nanomedicine company. The Company offers oncology nanomedicine treatments to control and treat cancer tumors. Nanobiotix serves customers in the United States and France.

Aldeyra Therapeutics, Inc. provides medical services. The Company deals in treatment and research for dry eye disease, allergic conjunctivitis, and other forms of ocular inflammation. Aldeyra Therapeutics serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aldeyra Therapeutics (ALDX US)

Aldeyra Therapeutics Inc (ALDX) - Wednesday, Apr 10, 2024

Mack885 identified buying opportunity in ALDX due to management's plan to address FDA setback. Perceptive Advisors increased stake in anticipation...

Value Investors Club

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)